Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Merck & Co., Inc. < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials August 29, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia August 27, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III August 26, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical August 09, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer August 08, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Second-Quarter 2024 Financial Results July 30, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma July 26, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Fourth-Quarter 2024 Dividend July 23, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants July 23, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024 July 16, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Completes Acquisition of EyeBio July 12, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Animal Health Completes Acquisition of Elanco’s Aqua Business July 09, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer July 01, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30 July 01, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults June 27, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza June 25, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults June 17, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma June 17, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma May 29, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Acquire EyeBio May 29, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Third-Quarter 2024 Dividend May 28, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC) May 28, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline May 15, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma May 13, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent May 09, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Participate in the Bank of America Securities 2024 Healthcare Conference May 08, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma May 01, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults April 29, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces First-Quarter 2024 Financial Results April 25, 2024 From Merck & Co., Inc. Via Business Wire Tickers MRK < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
